(redirected from AndroGel)
Also found in: Dictionary, Medical, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Words related to testosterone

a potent androgenic hormone produced chiefly by the testes

References in periodicals archive ?
The AndroGel (testosterone gel) brand and generic had US sales of approximately USD 815.6m MAT for the most recent twelve months ending in February 2019 according to IQVIA Health.
A federal jury in Chicago has ruled that United States-based AbbVie committed fraud in its marketing of AndroGel, its testosterone replacement therapy drug, it was reported yesterday.
Prior to Androgel's approval by the Food and Drug Administration (FDA), testosterone deficiency was not a condition most Americans knew about.
Based on the Endocrine Society Clinical Practice Guidelines, the starting dose for Androgel is 5-10 grams daily.
30-85 Same Ratio E1/E2 E2/P4 27.3 < 8.5 (L) 20.3 Ratio tTest/E2 24.9 > 45.8 (H) 12.9 (L) LH/FSH 3.6/2.5 0.6L/1.11 Other DHT/E2 Ra Dom 1.4H 18.8 (H) 12.4 (H) Taking: Androgel Androgel Same * Units No 1 1.62% x 4 1.62% x 5 Reconciled 8.1mg/d 10.1mg/d 54.7 mg/wk 70.7 mg/wk By RIA By ED/MS 11:24 Test: 7.28.15 7.28.15 8.25.15 Estrone Reference Interval Estradiol 14.9 Ref.
The FTC filed suit against Solvay on January 29, 2009, alleging that the settlement allowed Solvay to maintain a monopoly with its AndroGel drug since its patent might be found invalid.
More recently, though, the agency suffered a setback in its reverse payment suit against AbbVie and other defendants where it alleges that the patentees made an illicit reverse payment to the generic manufacturer to settle claims concerning testosterone drug AndroGel. The FTC claims that the patentees initiated "sham" litigation against generic manufacturer Teva, then settled the case by (1) permitting Teva to market a generic six years before the expiration of the relevant patent and (2) agreeing to license to Teva an authorized generic version of the cholesterol drug Tricor (it is alleged that Teva was having trouble obtaining FDA approval for its own generic version of Tricor).
Another massage therapist told ProPublica he found a tube of Androgel - a banned testosterone medication - in Salazar's condo.
Actavis, Solvay Pharmaceuticals obtained a patent for its FDA-approved, brand-name drug AndroGel. (64) Thereafter, generic manufacturers Actavis and Paddock each filed an ANDA that included a Paragraph IV certification claiming both that Solvay's patent was invalid and, even if it was valid, their drugs did not infringe upon the patent.
(33) In Actavis, Watson Pharmaceuticals and Paddock Laboratories had both filed ANDAs to market a generic version of Solvay's testosterone gel product AndroGel, and both included a paragraph IV certification.
(Watson) filed a Paragraph IV certified ANDA seeking approval to market a generic version of Solvay Pharmaceuticals' (Solvay) patented AndroGel, a topical gel that treats the symptoms of low testosterone in men.
Abbott (now AbbVie), which markets the bestselling Androgel, spent $20.8 million on testosterone ads in 2011 alone.
The high court dedared that the FTC could move forward with its antitrust lawsuit against Actavis, Solvay Pharmaceuticals, and others for participating in a legal settlement that delayed the introduction of generic products competing with AndroGel (testosterone gel) 1.62%.
The testosterone-boosting treatment AndroGel rose 41 percent to $364 million in the fourth quarter as the company increased television advertisements for the medicine.